Phenol derivatives and the pharmaceutical or cosmetic use thereof

1. A compound of formula (l):

in which:

R 1 represents a a hydrogen, a halogen, a methyl, an ethyl, an isopropyl, a trifluoromethyl, a nitrile, a nitro, a methoxy, an ethoxy, an isopropyl, a thiomethyl, a thioethyl, or a thioisopropyi;

R 2 represents a a hydrogen atom, a halogen, a methyl, an ethyl, an isopropyl, a trifluoromethyl, a nitrile, a nitro, a methoxy, an ethoxy, an isopropyl, a thiomethyl, a thioethyl, or a thioisopropyl;

R 3 and R 4 are identical or different and represent a hydrogen atom, a C 1-9 alkyl, a C 3-9 cycloalkyl, a C 1-6 fluoroalkyl, a —(CH 2 ) k —C 3-9 cycloalkyl, a —C 2-6 alkyl-OH, a —(CH 2 ) p —C 1-6 alkyloxy, a —(CH 2 ) k —C 3-7 cycloalkyl, a —(CH 2 ) k —C 1-6 fluoroalkyl or a —(CH 2 ) r —O—C 1-6 fluoroalkyl group,

optionally, the R 3 and R 4 groups together with the carbon atom form a C 3-9 cycloalkyl group or a heterocycle;

R 6 , R 6 , R 7 and R 8 are identical or different and represent a hydrogen atom, a C 1-6 alkyl, a C 3-7 cycloalkyl, a C 1-6 alkyloxy, a —S(O) g —C 1-6 alkyl, a C 1-6 fluoroalkyl, a C 1-6 fluoroalkyloxy, a —(CH 2 ) j —C 3-9 cycloalkyl, a —(CH 2 ) j —C 3-9 cycloalkyl, a —C 1-6 alkyl-OH, a —(CH 2 ) j —C 1-6 alkyloxy, a —(CH 2 ) j —C 1-6 fluoroalkyl, a —(CH 2 ) s —O—C 1-6 fluoroalkyl, COR e , CN, a NR 11 R 12 group, a halogen, or a phenyl;

and also a pharmaceutically acceptable salt, solvate or hydrate thereof and the conformer or rotamer thereof.

2. The compound as defined in claim 1 , wherein:

R 2 represents a hydrogen atom, a halogen, a methoxy, an ethoxy, a thiomethyl, a thioethyl or a trifluoromethyl group.

3. The compound of claim 1 , wherein R 3 and R 4 groups together with the carbon atom form a heterocycle selected from the group consisting of a tetrahydrofuran, a tetrahydropyran, a tetrahydrothiopyran, a tetrahydro-1-oxythiopyran, and a tetrahydro-1,1-dioxythiopyran.

4. A method of inhibiting androgen receptor activity, wherein the method comprises contacting an androgen receptor with a compound of claim 1 , a pharmaceutically acceptable salt thereof, a solvate thereof, a hydrate thereof, a conformer thereof or a rotamer thereof; and wherein the compound of claim 1 has a Kdapp dissociation constant of less than or equal to 500 nM.

5. The method of claim 4 , wherein the androgen receptor is expressed in a cell.

6. The method of claim 4 , wherein the compound has a Kdapp dissociation constant of less than or equal to 100 nM.

7. A composition comprising the compound of claim 1 , a pharmaceutically acceptable salt thereof, a solvate thereof, a hydrate thereof, a conformer thereof or a rotamer thereof.

8. The composition of claim 7 , wherein the composition is a pharmaceutical composition.

9. The composition of claim 7 , wherein the composition is a cosmetic composition.

10. The method of claim 4 , wherein the compound is selected from the group consisting of:

2-[(2-bromo-6-methoxypyridin4-ylamino)methyl]phenol;

2-[(2-chloropyridin-4-ylamino)methyl]phenol;

2-[(2-bromopyridin4-ylamino)methyl]phenol;

2-[(2-bromopyridin-4-ylamino)methyl]-4-fluorophenol;

2-[(2-methoxypyridin-4-ylamino)methyl]phenol;

2-[(2-bromo-6-methoxypyridin-4-ylamino)methyl]-4-fiuorophenol;

2-[(2-bromo-6-methyipyhdin-4-ylamino)methyl]phenol;

2-[(2-bromo-6-methylpyridin-4-ylamino)methyl]-4-fluorophenol;

2-[(2-bromo-6-methylpyridin-4-ylamino)methyl]-5-fluorophenol;

2-[(2-bromo-6-methoxypyridin-4-ylamino)methyl]-6-fluorophenol;

2-[(2-bromo-6-methoxypyridin-4-ylamino)methyl]-5-fluorophenol;

2-[(2-bromo-6-ethoxypyridin4-ylamino)methyl]phenol;

2-[(2-promo-6-methoxypyridin-4-ylamino)methyl]-5-methylphenol;

2-[(2-promo-6-methoxypyridin-4-ylamino)methyl]-6-methylphenol; and

2-[(2-trifluoromethylpyridin-4-ylamino)methyl]phenol.